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Deficiency of growth hormone (GH) in adults results in a syndrome characterized by
decreased muscle mass and exercise capacity, increased visceral fat, impaired quality of
life, unfavorable alterations in lipid profile and markers of cardiovascular risk, decrease in
bone mass and integrity, and increased mortality. When dosed appropriately, GH replace-
ment therapy (GHRT) is well tolerated, with a low incidence of side effects, and improves
most of the alterations observed in GH deficiency (GHD); beneficial effects on mortality, car-
diovascular events, and fracture rates, however, remain to be conclusively demonstrated.
The potential of GH to act as a mitogen has resulted in concern over the possibility of
increased de novo tumors or recurrence of pre-existing malignancies in individuals treated
with GH. Though studies of adults who received GHRT in childhood have produced con-
flicting reports in this regard, long-term surveillance of adult GHRT has not demonstrated
increased cancer risk or mortality.
Keywords: growth hormone, adult growth hormone deficiency, growth hormone risks, insulin-like growth factor-I,
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INTRODUCTION
Adult growth hormone deficiency (AGHD) results in a clini-
cal syndrome characterized by alterations in body composition,
diminished aerobic exercise capacity and quality of life (QoL),
and adverse changes in lipid and carbohydrate metabolism and
cardiovascular function (Hazem et al., 2012). A growing body of
evidence shows increased mortality in untreated AGHD patients
(Rosén and Bengtsson, 1990). Treatment of AGHD patients with
growth hormone replacement therapy (GHRT) normalizes many
of these signs and symptoms, improves QoL, and may possibly
enhance longevity (Rosén and Bengtsson, 1990; Hazem et al.,
2012). Although a theoretical increased risk of developing new or
recurrent neoplasms has been suggested in some studies evaluat-
ing adults who had been treated for GHD as children, this increase
has not been found in most studies of treatment in patients with
adult-onset GHD (Svensson and Bengtsson, 2009).
Identifying GHD in adults can be difficult due to similarities
with normal senescence. Due to the lack of specific biomarkers
for GHD, provocative biochemical testing is necessary to diagnose
AGHD with adequate accuracy, but currently available tests are
complex and may have significant side effects. A novel approach
to diagnosis of AGHD has been the use of ghrelin mimetic GH
secretagogues. These tests may offer a safe and reliable alternative
to the insulin tolerance test (ITT) or the glucagon stimulation test
(GST) for diagnosing AGHD.
Safety with long-term use and the cost effectiveness of GHRT
have not been clearly determined in past studies. In addition, a
growing incidence of acquired GHD related to traumatic brain
injury (TBI) presents a new sub-population of GHD patients and
consequently potentially increased numbers seeking treatment.
This review summarizes current understanding of the benefits
and possible risks of GHRT, as well as recommendations for test-
ing for GHD in adults, appropriate dosing, and monitoring for
efficacy and cost effectiveness of GHRT.
BACKGROUND
Many of the clinical features of AGHD resemble aspects of normal
aging. AGHD is a clinical syndrome associated with alterations in
body composition with reduced bone and muscle mass, dimin-
ished exercise performance and cardiac capacity, and altered lipid
metabolism with increase in adiposity (Kargi and Merriam, 2011).
AGHD has also been associated with impaired cognition as well as
having psychological impact (Deijen et al., 2011). All these features
result in decreased QoL. The syndrome of AGHD may contribute
to the increase in morbidity and mortality among patients with
hypopituitarism.
INCIDENCE
Three nationwide registries in Denmark using uniform standard-
ized criteria to diagnose adult-onset GHD estimated 19 cases per
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million for males and 14.2 cases per million for females, with an
increasing incidence in age with males but not with females. Those
individuals age 45 and older demonstrated the gender disparity not
seen in younger patient populations. AGHD has been estimated
to affect 1 per 100,000 people annually, while its incidence rate is
approximately 2 per 100,000 when child-onset GHD individuals
transition to adulthood (Stochholm et al., 2006).
PREVALENCE AND ETIOLOGY
Approximately 6,000 new cases of adults with GHD are diag-
nosed each year in the US. Some, 15–20% of those cases rep-
resent the continuation of child-onset GHD into maturity; the
remainder have adult-onset GHD resulting from damage to the
hypothalamic-pituitary axis (Gharib et al., 1998). Such damage
most commonly arises from pituitary or peri-pituitary tumors,
or by their treatment. Pituitary adenomas and their treatment
account for nearly two-thirds of AGHD cases (Bates et al.,
1996).
In addition to tumors and those adults who transition from
child-onset GHD, a growing number of cases of GHD have been
reported after TBI (Schneider et al., 2007). Most cases of GHD and
other post-traumatic hypopituitarism (PTHP) have been diag-
nosed within 1 year of trauma, but there have been cases that
developed nearly 40 years later (Edwards and Clark, 1986; Gunn
et al., 1991) leading to speculation that unless patients were specif-
ically questioned about past head trauma, many of these cases had
been classified as idiopathic (Benvenga et al., 2000).
The mechanism of GHD or other hypopituitary disorders
resulting from TBI is not clearly understood, but may reflect
both hypothalamic and pituitary damage as well as disruption
of hypothalamic-portal transport of growth hormone-releasing
hormone (GHRH) and other regulatory peptides. It is thought
that injury to the somatotrophs in the anterior pituitary, where
GH is produced and released, may predispose these cells to anoxia,
vascular insufficiency, or stalk injury. The long hypophysial ves-
sels, which provide oxygen and nutrients to the anterior pituitary
and the portal capillaries in the stalk, which transport hypothal-
amic regulatory peptides, are both highly vulnerable to traumatic
injury, resulting in disrupted portal transport of GHRH or even
anterior lobe infarction. Direct injury to the pituitary gland, result-
ing in edema of the diaphragma sella, can also result in anterior
lobe infarction. Injuries to the hypothalamus, anterior pituitary,
or pituitary stalk have been reported in 26–86% of patients who
have died from TBI during autopsy (Daniel et al., 1959; Ceballos,
1966; Kornblum and Fisher, 1969; Crompton, 1971; Pierucci et al.,
1971). In more recent studies, preliminary data suggests a possi-
ble association of certain apolipoprotein E polymorphisms with
the development of TBI-induced pituitary dysfunction (Tanriverdi
et al., 2008). The prevalence of post-traumatic AGHD can range
from 9 to 28%; but this range may be severely underestimated,
since many of studies have relied on insensitive biomarkers such
as insulin growth factor-1 (IGF-1) to screen for GHD. This varia-
tion highlights the challenges for the accurate diagnosis of GHD
in this sub-population (Bondanelli et al., 2004; Dimopoulou et al.,
2004; Lieberman et al., 2008).
Traumatic injury is the leading cause of death and disability in
young adults (Klasbeek et al., 1980; National Institutes of Health,
1998; van Baalen et al., 2003). It is estimated that 0.6–1.9 million
dollars per person to over 5 million persons living with the seque-
lae of TBI is spent in overall healthcare costs and associated loss of
productivity (McGregor and Pentland, 1997; Masel, 2004). TBI has
been called the “signature injury” of the current wars in Southwest
Asia. Over 10–20% of service members returning from a combat
deployment have reported suffering at least one blast injury (Terrio
et al., 2009). Fatigue, depression, irritability, cognitive impairment,
and decreased QoL; symptoms associated with GHD, resemble
another characteristic invisible injury of combat; post-traumatic
stress disorder. As many as 25% of TBI survivors may go undiag-
nosed, which may contribute to long-term adverse consequences
of untreated GHD. The implications of post-traumatic induced
GHD demand a clear consensus for diagnosis, treatment, and
management in this sub-population.
CLINICAL FEATURES OF GHD
The function of several organ systems is directly altered by the loss
of the physiologic effects of GH. Acquired isolated GHD is char-
acterized by weight gain, increased fat mass, and decreased lean
body mass (LBM). AGHD patients have 7% higher total body fat,
with similarly decreased LBM (Cuneo et al., 1992; Carroll et al.,
1998). Central adiposity lends to increased waist:hip ratio. In addi-
tion, triglyceride levels are increased and high density lipoprotein
(HDL) levels decreased. This alteration in lipid levels may explain,
in part, the observation of increased intima-medial wall thickness
(IMT), as measured by carotid ultrasonography, in this population
(Leonsson et al., 2002; Murata et al., 2003; Abs et al., 2006). These
factors may contribute to the increased incidence of cardiovascular
mortality seen in patients with GHD.
Decreased muscle mass and strength are also present in GHD
patients. In the heart, these changes are manifested by reduction
in left ventricular mass, decreased fractional shortening of car-
diac myocytes, and decreased cardiac output. Such abnormalities
may contribute to the decline in exercise capacity. Amato et al.
(1993) demonstrated a reduction in exercise capacity by 20–25%
in GHD patients compared to normal controls. In addition, cor-
tical bone density and trabecular bone density measurements in
GHD patients were 2.8 and 1.5 SD, respectively, below the mean
age and sex matched controls (Amato et al., 1993; O’Halloran et al.,
1993).
Patients with GHD appear to have impaired psychological
well-being and potentially significant neuropsychiatric manifesta-
tions, such as difficulty concentrating and memory impairment
(McGauley et al., 1990). The psychological general well-being
(PGWB) scale was adapted by McKenna et al. (1999) to determine
a measurable index of six dimensions of subjective well-being or
distress. A version of the QoL-assessment of growth hormone
deficiency in adults (QoL-AGHDA) questionnaire is shown in
Table 1. Reduced vitality, fatigue, social isolation, and depression
were consistently reported on self-rated questionnaires (Dupuy,
1984; McKenna et al., 1999). Other tools like the KIMS patient
life situation form (KIMS PLSF) (Moock et al., 2009), Euro-QoL,
EQ-5D (EuroQoL Group, 1990), and Nottingham health profile
(NHP) (Hunt et al., 1981) have been developed to measure QoL
and assess psychological well being (Hunt and McKenna, 1992;
Saller et al., 2006; Koltowska-Häggström et al., 2009). It is unclear
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Table 1 | Adult growth hormone deficiency quality of life assessment
(QoL-AGHDA) (reproduced from McKenna et al., 1999).
Yes No
I have to struggle to finish jobs
I feel a strong need to sleep during the day
I often feel lonely even when I am with other people
I have to read things several times before they sink in
It is difficult for me to make friends
It takes a lot of effort for me to do simple tasks
I have difficulty controlling my emotions
I often lose track of what I want to say
I lack confidence
I have to push myself to do things
I often feel very tense
I feel as if I let people down
I find it hard to mix with people
I feel worn out even when I’ve not done anything
There are times when I feel very low
I avoid responsibility if possible
I avoid mixing with people I don’t know well
I feel as if I am a burden to people
I often forget what people have said to me
I find it difficult to plan ahead
I am easily irritated by other people
I often feel too tired to do the things I ought to do
I have to force myself to do all the things that need doing
I often have to force myself to stay awake
My memory lets me down
Instructions: indicate whether each of the following statements below applies to
you. Scoring: 1 point for each “yes” answer.
Used with permission from Pfizer Inc.
however whether this impairment in psychological well being is
due specifically to reduced levels of GHD.
The signs and symptoms of GHD are summarized in Table 2
(Cuneo et al., 1992; Carroll et al., 1998).
DIAGNOSIS OF GHD
Given the lack of specific clinical marker for GHD in adults, bio-
chemical confirmation of the diagnosis is essential and usually
entails a stimulation test with a substance that triggers a rise in GH
in normals. Because the specificity of all available tests is imper-
fect, testing should be reserved for those patients whose clinical
presentation would yield a high pre-test probability of GHD, or
if there is evidence of other pituitary-dependent hormones that
would put them at risk of GHD, in order to decrease the rate of
false positives.
Testing is indicated for patients with structural disease affecting
the hypothalamus or pituitary, history of prior surgery to these
areas, history of head trauma or subarachnoid hemorrhage, or
documented deficiencies in other pituitary hormones (Cook et al.,
2009; Molitch et al., 2011). Low levels of insulin-like growth factor-
I (IGF-I) levels can be diagnostic in severe GHD, but since IGF-I is
often normal in AGHD, it is often necessary to confirm diagnosis
with provocative testing (Kargi and Merriam, 2013).
Table 2 |The syndrome of adult growth hormone deficiency (Cuneo
et al., 1992; Carroll et al., 1998).
Increased fat mass (especially central adiposity)
Decreased lean body mass
Decreased muscle strength
Decreased exercise performance
Decreased cardiac capacity
Decreased bone mineral density and increased risk of fracture
Atherogenic lipid profile
Thin, dry skin
Psychosocial problems and decreased quality of life
Fatigue
Depression
Anxiety
Impaired sleep
Social isolation
Hartman et al. (2002) reported that total IGF-I concentrations
less than 84 mcg/L (11 nmol/L) in the presence of three or more
pituitary hormone deficiencies the diagnosis of GHD can be made
with 95% accuracy. IGF-I bioactivity however may be even more
sensitive than total IGF-I levels, demonstrating a CI of 81.9 ver-
sus 63.8% in GHD patients (Varewijck et al., 2011). With these
notable exceptions, provocative testing is still warranted in that
nearly 58.5% of severely GHD patient have total IGF-I levels within
age-related normal range (Cianfarani et al., 2005). Age, gender, and
obesity interplay in IGF-I concentrations in GHD patients. There is
an overlap of age-related decline in IGF-I levels in normal subjects
and GHD patients with increasing age. GHD patients demon-
strated 4% (n= 48), 30% (n= 61), and 40% (n= 43) IGF-I levels
within the normal range limits for 20–39, 40–59, and over 60 years
of age, respectively (Hilding et al., 1999). Prior reports have shown
a much higher percentage of overlap, with range 34.8, 60.8, and
84.5% total IGF-I levels above the age-related third percentile lim-
its for the same age ranges (Cianfarani et al., 2005). IGF-I levels
are generally lower in female GHD patients versus male counter-
parts, but the exact mechanism is unclear and warrants further
investigation (Fisker et al., 1999).
The ITT is still considered the“gold standard”diagnostic test for
GHD, and should be considered as the initial test, unless there are
contraindications to its use. Because it induces hypoglycemia, it is
contraindicated in patients with coronary artery disease, seizures,
and in the elderly (Biller et al., 2002).
The combination of GHRH with arginine (GHRH+ARG) was
endorsed by several consensus guidelines as a comparably accu-
rate alternative to ITT, especially when ITT is contraindicated
(Aimaretti et al., 1998; Ho and Participants,2007;Yuen et al., 2009).
However, in 2008 EMD Serono, Inc. discontinued the manufac-
ture of GHRH (Geref ®) in the US. The unavailability of GHRH
increased the need for identifying reliable alternative GH stimu-
lation tests to diagnose AGHD with similar accuracy when ITT is
contraindicated or logistically difficult to perform.
Several studies have since shown that the GST is as reliable
as the ITT in discriminating GH-deficient and normal adults
(Spathis et al., 1974; Conceição et al., 2003; Yuen et al., 2009).
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Gomez et al. and Conceicao et al. demonstrated that the glucagon
test reliably identified controls and GHD patients. Using a peak
GH level of 3 ng/mL as a cutoff provided the best sensitivity (100
and 97%, respectively) and specificity (100 and 88%, respectively)
by receiver-operating characteristic (ROC) curve analysis (Gómez
et al., 2002; Conceição et al., 2003; Berg et al., 2010; Yuen, 2011).
The study of Berg et al. (2010) reported somewhat lower accuracy –
95% sensitivity and 79% specificity with a cutoff set at 2.5 ng/mL,
most likely reflecting a difference in the subject population tested.
Growth hormone secretagogues, such as ghrelin and ghrelin
mimetics (hexarelin, macimorelin, and GH-releasing peptide 2
and 6 – all currently still investigational) have also been studied for
use in diagnosing AGHD. With macimorelin, an orally active GH
secretagogue, a recent study reported that peak GH (an optimal cut
point of 2.7 ng/mL) offered 82% sensitivity, 92% specificity, and
87% accuracy (Garcia et al., 2013). In general macimorelin was well
tolerated; and compared to other stimulation tests, GH responses
were rapid and the test does not require parental administration
of agents.
Consensus guidelines for the evaluation of adult GHD state that
any of these dynamic tests can be used to diagnose GHD, including
the ITT, the GST, the combined GHRH–ARG test (where avail-
able), and likely the ghrelin mimetics when further validated. Age,
gender, and BMI may blunt the response of some stimulatory tests.
Further investigation is warranted in determining the best cut off
values to enhance the sensitivity in diagnosing GHD in this subset
population (Colao et al., 2009). Table 3 provides a comparison
chart for GH provocative tests.
TREATMENT OF GHD; BENEFITS OF GHRT
There is a general consensus that many of the metabolic and psy-
chological abnormalities associated with GHD can be reversed
with GH replacement. Lower doses of GH may decrease the
incidence of side effects from GHRT, while still achieving a clinical
response to therapy (Chein et al., 1999; Ahmad et al., 2001).
Treatment with GH results in profound changes in body com-
position, especially in reduced fat mass, and an increase in LBM.
The decline in fat mass is most significant in visceral and trunk
locations (9% reduction, compared with placebo-treated patients
who have a mean 4.3% increase in visceral fat mass over 6 months),
suggesting that GHRT may reverse the central adiposity associated
with GHD and potentially reduce the increased cardiovascular risk
that this body composition carries (Beauregard et al., 2008). The
increase in LBM is smaller than the reduction in fat mass, but
appears to be more sustained (Al-Shoumer et al., 1996; Hoffman
et al., 2004a; Götherström et al., 2009).
An overall beneficial effect on serum lipid profile (reduction
in total and LDL cholesterol and improvement in HDL choles-
terol) has been noted with GHRT in some studies, but data are
inconsistent (Florakis et al., 2000; Maison et al., 2004). When
GHRT is added to lipid management therapy with HMG CoA
reductase inhibitors (statins), it may promote a synergistic effect
(Monson et al., 2007). The reduction in atherosclerosis with use
of GHRT has been assessed by several studies evaluating carotid
IMT (Pfeifer et al., 1999; Leonsson et al., 2002; Murata et al., 2003;
Colao et al., 2008). In addition, GHRT has demonstrated improve-
ment in pro-inflammatory and other cardiovascular risk markers,
including C-reactive protein, apolipoprotein B, and homocysteine
levels (Sesmilo et al., 2000, 2001).
Growth hormone replacement has a positive effect on left ven-
tricular mass, interventricular septal and left ventricular posterior
wall thickness, left ventricular ejection diastolic diameters, and
stroke volume, via echocardiographic evaluation in adults with
GHD (Maison and Chanson, 2003). It improves both exercise
capacity and cardiac function (Widdowson and Gibney, 2008).
These patients demonstrated increased oxygen uptake and power
output with cycle ergometry with increased skeletal muscle mass
and aerobic capacity.
Table 3 | Comparison of GH ProvocativeTests (Kargi and Merriam, 2013).
Test Protocol GH diagnostic cutoff Advantages Additional comments
Insulin-induced
hypoglycemia (ITT)
Regular insulin 0.1 units/kg IV 5 ng/mL Gold standard test Risk of serious side effects
Measure glucose, GH, and cortisol
at baseline and every 30 min for 3 h
Simultaneously
assesses HPA axis
Significant contraindications
Resource intensive
GHRH-Arg GHRH 1µg/kg
Arginine 0.5 g/kg over 30 min
Measure GH at baseline and every
30 min for 3 h
BMI <25: 11 ng/mL
BMI 25–30: 8 ng/mL
BMI >30: 4 ng/mL
Low risk of side effects GHRH not commercially
available in US
Low sensitivity for GH diagnosis
in patients with hypothalamic
etiologies of GHD
Glucagon stimulation
test (GST)
Glucagon 1 mg i.m. or s.c. (1.5 mg
for patients >90 kg), not i.v.
3 ng/mL Glucagon readily
available
Side effects (nausea, vomiting,
headache)
Measure glucose and GH (and
cortisol if desired) at baseline and
every 30 min for 4 h
GH secretagogues
(ghrelin and ghrelin
mimetics)
1 mcg/kg IV
Measure GH response every 15 min
for 120 min
BMI <25: 7.3 ng/mL)
BMI 25–30: 2.9
BMI >30: 0.6
GH peak in 60 min Oral formulation; side
effect – bad taste (macimorelin)
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Growth hormone replacement therapy results in a bipha-
sic change in bone mineral density (BMD), with an initial 6–
12 months period of increased bone resorption followed by an
overall increase in bone mass. After long-term treatment, BMD
continues to rise even 18–24 months after discontinuation of
GHRT (Baum et al., 1996; Johannsson et al., 1996; Biller et al.,
2000). Typically a 4–10% increase in BMD has been reported,
with generally greater effects in vertebral trabecular bone com-
pared to femoral sites (Baum et al., 1996; Biller et al., 2000; Shalet
et al., 2003). In general individuals with the most severe bone
loss had the greatest positive response to treatment, and BMD
in men responded to a greater degree than BMD in women,
perhaps reflecting estrogen-mediated inhibition of GH action
through stimulation of suppressor of cytokine signaling-2 (socs2)
(Johannsson et al., 1996; Drake et al., 2001; Bex et al., 2002).
There appears to be no single factor that completely accounts
for the increased mortality seen in untreated GHD adults when
compared to age and sex matched controls (Rosén and Bengts-
son, 1990; Hazem et al., 2012). The two most prominent causes
of premature mortality in GHD patients are cardiovascular and
cerebrovascular disease. Despite several studies of the effects of
chronic GH replacement on mortality, the evidence of increased
longevity is still not strong enough to be conclusive (van Bunderen
et al., 2011; Gaillard et al., 2012).
The majority of GHD patients report enhanced QoL after start-
ing GHRT as assessed both by self-rating questionnaires and by
objective measures such as days absent from work and economic
success. The severity of QoL impairment before therapy with GH
is the strongest predictor of treatment response (Murray et al.,
1999). QoL measures improve as soon as 3 months after initiat-
ing GHRT, and long-term studies shows a continued benefit for
10 years (Drake et al., 1998; Gilchrist et al., 2002; Rosilio et al.,
2004).
INDICATIONS FOR GH REPLACEMENT
Prior to 1996 the use of GH in the US was limited to promot-
ing statural growth in children with confirmed GHD; its use to
promote growth in other conditions associated with short stature,
such as Turner syndrome, was approved subsequently. It has only
been in the past 20 years that compelling evidence for a clinical
syndrome in adults with GHD has been published and widely
accepted. While several consensus guidelines have been published
on the management of AGHD with GH replacement, the optimal
criteria to select patients who might best benefit from treat-
ment remains controversial, and practices vary among individual
practitioners and countries.
In general it is recommended that only adults with confirmed
GHD based on published criteria be evaluated for treatment. Indi-
viduals most likely to benefit from GH replacement include those
with severe GHD, defined by GH provocative testing response and
serum IGF-I levels. Other appropriate indications for initiation
of GHRT are osteopenia, adverse cardiovascular risk profile, and
reduced QoL, as measured from validated QoL questionnaires.
Continuation of therapy is generally recommended for adoles-
cents transitioning to adulthood even after completion of linear
growth, to allow full skeletal and muscle maturation, which can
continue for a further decade (Bex et al., 2002; Baroncelli et al.,
2003; Shalet et al., 2003; Underwood et al., 2003). Discontinuation
of GHRT based on reaching final adult height in this transitioning
population of GHD patients has also been associated with wors-
ening of lipoprotein profiles, body composition, and QoL scores
(Underwood et al., 2003; Mauras et al., 2005) GH therapy in this
population should therefore be interrupted as briefly as possible,
optimally only for re-testing to confirm persistent GHD.
INITIATION AND MONITORING OF GH TREATMENT
Unlike pediatric GH treatment, often dosed in micro-
grams/kilograms of body weight/day, currently recommended GH
replacement dosing in adults is individualized independent of
weight, taking into account the patient’s age, gender, and estrogen
status (Johannsson et al., 1997a; Hoffman et al., 2004b). Initiating
therapy at low doses (total dose 0.2–0.4 mg/day SC) decreases the
likelihood of developing common side effects like joint stiffness,
arthralgias, myalgias, paresthesias, and peripheral edema, with
fluid retention. The dose should be titrated at 6–8 week intervals
based on clinical response, while avoiding side effects and moni-
toring serum IGF-I levels. Achieving a target in the upper half of
normal age adjusted IGF-I range is desired. It is reasonable to start
with higher doses (0.4–0.5 mg/day) in patients less than 30 years
of age, but older patients (greater than 60 years of age) should be
started on lower doses (0.1–0.2 mg/day) and titrated more slowly
to minimize occurrence of side effects. Some childhood-onset
AGHD patients with very low pre-treatment IGF-I may develop
GH side effects but still not reach mid-normal levels despite high
GH doses.
Women taking oral estrogen replacement may require higher
doses of GHRT, presumably because oral estrogen inhibits liver
IGF-I production and secretion by a first pass effect (Weissberger
et al., 1991). No dose adjustment is usually needed in patients on
moderate doses of transdermal estrogen.
Once dosing is stabilized, clinical evaluation and assessment
for side effects along with measurement of IGF-I levels should
be performed at 6 month intervals. Fasting lipid profiles and fast-
ing glucose levels should be checked annually and after any GH
dose increase. Blood pressure, weight, waist circumference, and
BMI should be checked annually and at each clinic visit. Base-
line bone DEXA scan should be performed and then rechecked
every 2 years if the baseline is abnormal. Optimally QoL mea-
sures should be assessed at baseline and then at least annually
while on GHRT to monitor treatment response (Cook et al., 2009;
Koltowska-Häggström et al., 2009).
The duration of treatment for AGHD has not been defined.
If therapy is tolerated, with a good clinical response to treatment
noted, then there is no particular reason to discontinue therapy.
Conversely if there is no perceived or biochemical benefit of treat-
ment after at least 1 year of therapy, then stopping GHRT may be
appropriate.
Tables 4 and 5 summarize the 2009 AACE recommendations
for GHRT dosing and monitoring (Cook et al., 2009).
NOVEL GH FORMULATIONS AND ANALOGS
Traditional treatment of GHD has been with the use of daily
subcutaneous injections of recombinant human growth hormone
(rhGH). This schedule however, is too infrequent to reproduce
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Table 4 | Factors that may affect GH dosing [adapted from AACE 2009
(Cook et al., 2009)].
Increase GH dose Decrease GH dose
Younger patients (regardless
of onset type)
Older patients
Low IGF-I levels High IGF-I levels
Oral estrogen use Discontinuing oral estrogen/change to
transdermal estrogen use
To induce lipolysis Testosterone use (not always necessary}
Worsening glucose tolerance
Side effects
Reprinted from endocrine practice, vol. 15 (Cook et al., 2009), with permission
from the American Association of Clinical Endocrinologists.
Table 5 | Recommendations for GH replacement therapy in AGHD
(adapted from Cook et al., 2009).
Starting dose
Age <30 years: 0.4–0.5 mg/day (may be higher for patients transitioning
from pediatric treatment)
Age 30–60 years: 0.2–0.3 mg/day
Age >60 years: 0.1–0.2 mg/day
Use lower GH doses (0.1–0.2 mg/day) in all patients with diabetes or
who are susceptible to glucose intolerance
Dose titration
At 1–2 month intervals, increase dose by 0.1–0.2 mg/day based on
clinical response, serum IGF-I levels, side effects, and individual
considerations such as glucose intolerance
In older patients consider longer time intervals and smaller dose
increments
Goal
Aim for serum IGF-I levels in the middle of the normal range appropriate
for age and sex, unless side effects are significant
Consider a trial of higher GH doses to determine additional benefit as
long as serum IGF-I levels remain within normal range and no adverse
side effects reported
Reprinted from endocrine practice, vol. 15 (Cook et al., 2009), with permission
from the American Association of Clinical Endocrinologists.
the multiple daily pulses of normal endogenous GH secretion,
and too frequent to be convenient for many patients, raising con-
cerns about adherence to treatment, which can lead to reduced
efficacy. Although rhGH when injected SC has a circulating half-
life of 5 h and is rapidly cleared by the liver and kidney, studies
have demonstrated comparable growth velocity and IGF-I levels
with continuous infusion pump therapy (Jørgensen et al., 1990;
Laursen et al., 1993, 1995, 2001; Tauber et al., 1993). This suggests
that longer-acting GH formulations and analogs, although even
more unphysiologic than daily injections, could be effective for
AGHD treatment.
A number of brands and formulations of rhGH are available;
in the US, GH preparations are available as lyophilized pow-
der in vials for reconstitution (Humatrope®, Nutropin®, Seros-
tim®, Saizen®, Zorbtive®, Tev-Tropin®, and Omnitrope®); in
two chamber cartridges requiring reconstitution (Genotropin®
and Saizen®); as a liquid in prefilled cartridges (Norditropin®,
Humatrope®, Nutropin AQ®, Saizen®, and Omnitrope®); or as
prefilled single-dose (Genotropin Miniquick®) or multi-dose
pens (e.g., Norditropin® Flexpro®, Norditropin®, Nordi-Flex®,
Nutropin AQ® – Nuspin™ , or Omnitrope® 5 or 10 mg pens).
Those with preservative-free diluents must be used within 24 h
of reconstitution, but others can be stored unrefrigerated for
14–28 days (Nutropin, 2006, 2008; Saizen, 2007; Serostim, 2007;
Tev-Tropin, 2007; Genotropin, 2009; Humatrope, 2009; Zorbtive,
2009; Norditropin, 2010; Omnitrope, 2010).
Besides daily GH, several longer-acting GH formulations
and analogs have been developed. The most fully studied
sustained-release formulation thus far is encapsulation of GH into
biodegradable polylactic acid-co-glycolic acid (PLGA) micros-
pheres, which showed sustained GH release profile for 1 month
(Johnson et al., 1997; Park et al., 2010). Nutropin Depot® was the
first GH delivery system launched using the PLGA microsphere
system, but was later taken off the market due to the high injec-
tion volumes and large-bore needles required, along with business
concerns over the manufacture (Govardhan et al., 2005).
A GH-loaded hyaluronate microparticle (LB03002) was devel-
oped and launched in Korea by LG Life Sciences in 2007. This
once a-week injection is currently the single commercially avail-
able sustained-release formulation of GH, at present approved
only in that country. In global Phase III study, treatment with
LB03002 for 26 or 52 weeks in adults with GHD demonstrated a
sustained reduction of fat mass and other body composition para-
meters, and was generally well tolerated with a good safety profile
(Biller et al., 2010; Péter et al., 2012).
PEGylation (the attachment of polyethylene glycol, PEG) has
also been used to extend the half-life of rhGH. The first PEGy-
lated rhGH (PHA-794428) was discontinued due to safety con-
cerns related to local injection-site lipoatrophy (Touraine et al.,
2009). Two other longer-acting GH extension peptides using
either albumin or an hCG-derived extension sequence are also
in development.
VRS-317 is a novel rhGH fusion protein (addition of hormon-
ally inert and relatively non-allergenic N- and C-terminal amino
acids extend the half-life of rhGH) that may provide a monthly
dosing option in GHD patients. In animal subjects, VRS-317 had
a half-life of approximately 110 h, and produced a sustained IGF-I
response for 1 month after a single dose. A Phase I trial of VRS-
317 in GHD adults has recently been completed. Preliminary data
show achievement of graded responses of IGF-1 at doses lower
than those typically used with daily rhGH, with no significant
drug related adverse events reported over the course of 1 month
(Bailey et al., 2012; Cleland et al., 2012). If these early results are
confirmed in multi-dose studies, monthly dosing could lead to
increased adherence and convenience.
SIDE EFFECTS AND RISKS, AND LONG-TERM SAFETY
CONCERNS
The most common side effects of GH treatment in GHD adults
result from fluid retention, with peripheral edema, arthralgias,
carpal tunnel syndrome, paresthesias, and worsening of glucose
tolerance. These hormonal side effects generally respond to dose
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reduction. Older and more obese patients are more susceptible to
side effects from GH treatment. In studies using higher than rec-
ommended doses of GH, more frequent adverse outcomes have
been observed (Johannsson et al., 1997a; Hoffman et al., 2004b).
Benign intracranial hypertension (pseudotumor cerebri) has
been linked to GH treatment in children (Malozowski and Stadel,
1995) but is rare in adults, with only one case reported (Malo-
zowski et al., 1993). Gynecomastia has been reported in normal
elderly individuals receiving GH in high doses (Cohn et al., 1993;
Blackman et al., 2002).
Another rare but reported complication of GH therapy is mac-
ular edema in non-diabetic patients. Koller et al. (1998) reported
two non-diabetic patients: one a non-obese 11-year-old girl receiv-
ing GHRT for Turner’s syndrome presenting with neovasculariza-
tion, and an obese 31-year-old male who had traumatic hypo-
thalamic injury and was started on GHRT 14 months prior to
presenting with decreased visual acuity. Of note, both cases had
their GH dose increased just prior to the onset of this complication.
Early clinical trials reported insulin resistance and diabetes
mellitus in patients receiving GHRT. These small initial studies
reported impaired fasting glucose and insulin levels within the
first year of GH therapy (Beshyah et al., 1994; Salomon et al.,
1994; al-Shoumer et al., 1998). In addition, data from the Pfizer
International Growth Database (KIGS) indicate that GH ther-
apy in children may give rise to an increased incidence of type
2 diabetes mellitus, heightening the concern for adults with GHD
receiving similar treatment (Cutfield et al., 2000). Many of the
early AGHD studies used weight-based dosing derived from pedi-
atric practice, and these fluid retention and hyperglycemic side
effects have become much less frequent as adult practice has
shifted to individualized dosing starting with lower doses and
gradually titrating upwards until target responses, benefits, or
side effects are encountered. Perhaps for this reason, long-term
GH replacement in adult patients with GHD has not usually led
to abnormal levels of plasma glucose or glycosylated hemoglo-
bin (Bengtsson et al., 2002). In fact, some studies of titrated GH
replacement for AGHD have been shown to improve insulin sen-
sitivity, at least in patients with features consistent with metabolic
syndrome (Johannsson et al., 1997b), suggesting that improved
body composition can at least partially counter the direct anti-
insulin actions of GH, although in non-obese subjects the net
effect of GH treatment is usually a mild increase in fasting glu-
cose and/or insulin within the normal range. Insulin sensitivity
varies based on the patient’s genetic predisposition, age, and body
composition (Hoffman et al., 2004a). Diabetes is not an absolute
contraindication to GHRT, but in individuals with diabetes or
predisposed to developing diabetes, it is recommended to titrate
the dose of GH even more slowly than in other patients, and to
adjust anti-diabetic medications as warranted to maintain glucose
homeostasis.
The generally benign side effect profile of replacement doses of
GH cannot be extrapolated to supraphysiologic dosing intended
to overcome GH resistance or to reverse catabolism. Takala et al.
(1999) reported increased mortality in parallel studies conducted
on critically ill patients treated with much higher doses of GH
(5.3–8 mg/day), more than 10-fold the doses often used in adult
GH replacement. Reasoning that these patients had resistance to
GH based on high GH levels but low serum IGF-I and IGF-binding
protein-3 concentrations, due to increased protein catabolism
and negative nitrogen balance, these investigators attempted to
reverse this catabolic state; but instead found a near-doubling
of the already high in-hospital death rate, though with no single
mechanism to which the increased mortality could be attributed.
Non-fatal fluid retention, which can be significant, is also more
commonly associated with high GH doses, particularly in older
patients (70% in Finnish study were 55 years of age and older
and 75% in the multinational study) (Johannsson et al., 1997a;
Hoffman et al., 2004b).
There is no evidence that GH replacement in adults increases
the risk of de novo or recurrent malignancy. For survivors of
childhood cancer, GH treatment may further slightly increase the
already increased risk of developing a second neoplasm, although
this increase was not seen in the large Childhood Cancer Survival
Study (Sklar et al., 2002). However, there are no comparable data
for adult GHRT. Most of the concerns about increased cancer rates
in GHD patients treated with GH have primarily focused on obser-
vational data on survivors of childhood leukemia, in whom cranial
irradiation frequently leads to GHD. These reports may be mis-
leading however, since it is not clear if tumor development noted
reflected a new or recurrent malignancy, or due to irradiation or
other past treatment of existing tumors (Swerdlow et al., 2002).
Notably, pediatric patients with “idiopathic” GHD did not have
an increase in new tumor growth when treated with GH (Fradkin
et al., 1993).
Despite the overall lack of a signal for increased risk, case
reports and a minority of series have noted development of can-
cers after treatment with GH. Magnavita et al. (1996) reported
a case of a semi-professional cyclist who developed Hodgkin’s
lymphoma nearly 4 years after several supra-therapeutic courses
of GH. Swerdlow et al. (2002) reported an increased incidence
of cancer formation in a cohort study of 1,848 patients in the
UK treated with GH from 1959 to 1985. Cancer incidence was
assessed in 1995 and again in 2000. Despite the author’s assertion
that there was a high incidence of cancer and mortality associated
with cancer, the total number of cancer diagnoses in the cohort
was only 12 – 2 colon cancer, 2 Hodgkin’s lymphoma, 2 bone can-
cer, and 1 each from mouth, liver, bile duct, cervix, ovary, and
testis. Only the first two increases were statistically significant. Of
note, one patient who developed colon cancer may have had famil-
ial polyposis. Despite the small number of cancer cases, there is
an epidemiological association of cancer rates in the setting of
increased IGF-I levels but not of IGF-binding protein-3 (IGFBP-
3), resulting in a high IGF-1 to IGFBP-3 ratio (Grimberg and
Cohen, 1999; Shim and Cohen, 1999; Cohen et al., 2000). IGF-1
has been detected in colorectal cancers and is a strong stimulator
of colorectal cancer cell proliferation in vitro (Lahm et al., 1994),
but GH treatment usually results in increases in both IGF-I and
IGFBP-3. There is no information on IGF-1 and IGFBP-3 mea-
surements in the Swerdlow report. The British patients in this
cohort were given high GH doses 2–3 times per week versus cur-
rent use of lower daily dosing, and this difference may also have
played a role in these findings. Data are currently lacking demon-
strating whether current GH dosing regimens promote any tumor
recurrence or re-growth (Frajese et al., 2001; Hatrick et al., 2002;
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Chung et al., 2005, 2008; Jostel et al., 2005; Karavitaki et al., 2006;
Buchfelder et al., 2007; Arnold et al., 2009; Olsson et al., 2009).
Growth hormone is a mitogen, however, and despite several
studies that show no demonstrated increased risk of malignancy
with GHRT, the use of GH is contraindicated in active malig-
nancy out of concern it might accelerate the growth of an existing
neoplasm (Frajese et al., 2001; Hatrick et al., 2002; Chung et al.,
2005, 2008; Jostel et al., 2005; Karavitaki et al., 2006; Buchfelder
et al., 2007; Arnold et al., 2009; Olsson et al., 2009). GH therapy
should be stopped in all patients with active malignancy until the
underlying condition is controlled.
USE OF GH IN NON-GHD ADULTS: NORMAL AGING AND
COMPETITIVE SPORTS
AGING
After achieving linear growth and full reproductive maturation,
GH levels begin to decline; primarily from reduced hypothalamic
secretion of GH-releasing hormone, which leads to lower GH lev-
els and reduction in serum IGF-I levels. These normal age-related
GH and serum IGF-I reductions are associated with age-related
changes that are similar to the signs and symptoms seen in GHD
adults. Based on this decline and in alterations in body com-
position, strength, and aerobic capacity that are also similar to
those observed in AGHD, though less severe, interest was piqued
in using GH therapy in healthy older patients. In 1990, Rudman
et al. (1990) reported reduced fat mass, increased muscle mass
and increased lumbar vertebral bone density in healthy men, age
60 and older, after 6 months of GH use compared to untreated con-
trols. Although no functional outcomes were reported, this paper
received wide publicity and led to subsequent studies looking to
confirm the possible anti-aging benefits of GH in healthy seniors,
as well as to rapid proliferation of anti-aging clinics offering GH
to middle-aged as well as older clients, even in the absence of any
confirmatory results.
Liu et al. conducted a systematic review of 31 articles looking
at 18 separate studies of GH treatment outcomes in healthy older
individuals. They concluded that only minimal body composi-
tion changes (2.1 kg reduction in fat mass, 2.1 kg increase in LBM,
and 0.29 mmol/L reduction in total cholesterol) without signifi-
cant change in bone density, other serum lipid levels or decrease in
body weight was seen with GH use. However, a higher number of
adverse events (edema, arthralgias, gynecomastia, development of
impaired fasting glucose, and diabetes) were reported (Liu et al.,
2007).
Blackman et al. (2002) evaluated effects of GH and/or sex
steroid treatment in older men and women in a 2-by-2 placebo-
controlled study. They reported that GH alone and GH with
testosterone similarly resulted in reduced fat mass and increased
LBM. Testosterone alone or the combination of GH with testos-
terone improved strength and exercise capacity whereas GH use
alone did not. Adverse effects were similar with and without sex
steroids; except for a higher rate of fasting glucose intolerance or
diabetes in men treated with GH only. These investigators initially
attempted to use GH doses similar to those employed by Rudman
and colleagues (Rudman et al., 1990; Blackman et al., 2002), but
were forced to reduce them by nearly 2/3 due to severe side effects.
The reasons for the lack of side effects in the Rudman report are
not clear.
Reports of effects of GH on BMD in non-GHD normal aging
are conflicting. Holloway et al. (1997) found statistically signif-
icant improvement in BMD in postmenopausal women treated
with GH, but concluded that the gains were substantially less than
what is seen with bisphosphonates or estrogenic hormone therapy,
with a higher incidence of adverse events. However, other studies
did not demonstrate BMD increase with GH treatment in this
population (Gurlek and Gedik, 2001; Christmas et al., 2002).
Metformin and GH did not appear to be superior to met-
formin alone in reducing total body fat or waist circumference
in older patients with metabolic syndrome and elevated fasting
plasma glucose levels (Herrmann et al., 2004).
In a placebo-controlled study, Baker et al. (2012) demon-
strated favorable effects on cognition in both healthy older adults
and those with amnestic minimal cognitive impairment (MCI)
with 20 weeks of daily self-injection with a degradation-protected
GHRH analog to boost GH secretion. Treatment with GHRH,
which boosted GH secretion and IGF-I levels resulted in improve-
ments in executive functioning and verbal memory. Visual mem-
ory was not enhanced. Though GHRH was generally well tolerated,
subjects on active treatment were twice as likely to have adverse
effects, usually mild, compared to those in the placebo arm.
Thus the use of GH to counter some effects of normal aging is
still highly controversial. Most studies have shown some improve-
ments in body composition, but failed to show an increase in
cardiovascular endurance or muscle strength (Blackman et al.,
2002; Liu et al., 2007). Additionally more adverse events were
reported in the GH treatment groups. Given that both the baseline
and target differ from AGHD, with baseline levels that although
lower than in young normals are higher than in GHD, and target
levels above age-matched normals and similar to those in healthy
young adults. It is unclear if the mix of benefits, side effects, and
risks will be similar to those in AGHD, particularly with use over
longer durations than the maximum 1 year in current controlled
studies. Thus GH treatment in otherwise healthy seniors cannot
be recommended other than in controlled clinical research stud-
ies, and its use for anti-aging purposes is currently prohibited by
US Federal law, 21 U.S.C. §333(e), making GH the only legal drug
for which off-label prescribing is illegal in two circumstances. The
other prohibition is for use to boost athletic performance.
ATHLETICS
Anecdotal evidence suggests that GH and IGF-I are frequently
abused by athletes for their anabolic and lipolytic properties. GH
has been touted to achieve faster recovery from injury and enhance
ergogenicity, although there is no evidence that GH or IGF-I actu-
ally improves competitive performance in young healthy adults
(Healy and Russell-Jones, 1997; Holt and Sonksen, 2008; Liu et al.,
2008; Baumann, 2012). Conducting randomized controlled clini-
cal trials is challenging, due to frequent concomitant use of insulin
and anabolic steroids. GH and IGF-I appear on many lists of pro-
hibited substances in competition, and their use is banned by the
World Anti-doping Agency (WADA). As noted, in the US, admin-
istration of GH (but not IGF-I, GHRH, or ghrelin mimetic GH
secretagogues) to enhance athletic performance is legally prohib-
ited, though rarely prosecuted; legal proceedings have generally
been based on false testimony about its use rather than the use
itself. GH may be appealing to athletes seeking an edge; given its
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short half-life in circulation its abuse is difficult to detect except
in extremely high doses (Baumann, 2012). Increased IGF-I stimu-
lated by GH self-administration does not qualitatively differ from
that which is supported by endogenous GH. Although synthetic
GH contains just one molecular weight isoform, while endogenous
GH secretion is a mix of 20 and 22 kD isoforms, it is rapidly cleared
from the circulation and so testing needs to be done within just
hours after dosing (Baumann, 2012). Liu et al. (2008) conducted
a systematic review of 27 randomized, controlled trials involving
303 young, lean, physically fit subjects receiving GH at an average
dose of 2.5 mg/day, a 5- to 10-fold excess over the physiological GH
production rate. As expected, body composition changes (increase
LBM and reduced fat mass) were noted, but there were no differ-
ences in strength or exercise capacity between those taking GH and
those not. One of the limitations he noted in these studies was the
shorter duration of use and lower dose of GH compared to what
is typically abused by athletes. The typical side effects associated
with GH overdose (edema, arthralgias, carpal tunnel syndrome,
and sweating) were observed in 15–44% of the participants (Holt
and Sonksen, 2008).
COST EFFECTIVENESS
Managed care payers should utilize evidence-based review to
determine appropriate criteria for reimbursement for GH ther-
apy. Despite the positive effects of GH replacement treatment on
body composition and markers of cardiovascular disease in adults
with GHD, it is difficult to measure the therapeutic benefits of
GHRT with precision after linear growth has been completed. In
addition, despite multiple studies, data showing that GHRT in
GHD adults actually reduces mortality are still inconclusive (Fra-
jese et al., 2001). With the lack of other effective treatment outcome
measures, the use of “softer” endpoints such as QoL, have been
used to justify the cost effectiveness of GHRT.
Using quality adjusted life years (QALY) measures, a cost-utility
analysis of GHRT may be feasible. QALY, a frequently used health
status index, combines information on the length of life (quantity)
and the QoL, where the latter is measured by utilities on a scale
that has values of 1 and 0 for full health and death, respectively
(Torrance, 1987). The QALY unit is therefore defined as 1 year of
life with full health.
Cost-utility analysis based on QALY change is the most widely
recognized method in pharmacoeconomic evaluation, and QoL-
AGHDA was used by the UK National Institute for Health and
Clinical Excellence (NICE) as a potential source of outcomes data
for such an evaluation (McKenna et al., 1999). The NICE Commit-
tee agreed that the QoL-AGHDA questionnaire is the best validated
available evaluation tool for the assessment of both baseline QoL
and the effect of treatment in adults with GHD (Table 1), and
concluded that a trial of GH treatment could be recommended for
adults with GHD who have perceived severe impairment of QoL,
as demonstrated by a reported score of at least 11 in the QoL-
AGHDA. Upon examination of available evidence, the Committee
found that the subgroup of adults with GHD for whom treatment
may be clinically justified are those who have an improvement in
QoL equivalent to an absolute change of at least seven points over
their baseline score. The Committee stated that re-assessment of
the need for GH replacement should take place after a trial treat-
ment period of at least 9 months (3 months for dose titration and
6 months for assessment of response). For GH treatment to con-
tinue after this trial period, they recommended that one demon-
strate a sustained improvement in QoL over the pre-treatment
baseline. These recommendations are widely used in determin-
ing coverage for GH for patients covered by the National Health
Service, but less universally adopted outside the UK.
In the US, many insurers have developed policies that set spe-
cific criteria for approved indications for coverage of GH replace-
ment in AGHD and to guide clinicians with appropriate dosing,
monitoring, and assessing cost effectiveness of GHRT. Some are
evidence-based and follow the recommendations of the 2009
AACE or the 2011 Endocrine Society clinical practice guidelines
but others are arbitrary and in some cases at variance with best
practices (Cook et al., 2009; Molitch et al., 2011).
CONCLUSION
Despite absence of the prominent biological marker of linear
growth, AGHD has characteristic, if non-specific signs and symp-
toms. Many of these can be reversed with appropriate GHRT.
Determining who should be tested and treated for GHD can be
challenging with the relative insensitivity of simple available bio-
chemical markers such as IGF-I. And current dynamic testing
procedures are either complex or attended with significant side
effects or risks, or both. Reliable and safe alternative diagnos-
tic tools are therefore needed. Stimulation testing using ghrelin
mimetics appears promising but is not yet clinically available.
Research is ongoing in developing longer-acting and therefore
more convenient preparations of GHRT to promote better com-
pliance and clinical efficacy. It appears at this time that cost-
benefit and cost effectiveness data for GHRT favors treatment
in clinically symptomatic patients with confirmed GHD. Despite
the validated beneficial effects of GHRT in adults – including
improvements in body composition, lipid profile, QoL and BMD –
shown in many studies, some controversies remain with regards
to whether long-term use of GH might promote tumor initiation
or recurrence.
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